CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myelomaTobias Bexte, Evelyn Ullrich, Emilia Salzmann‐Manrique et al.|OncoImmunology|2022Cited by 77
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell ImmunotherapyPhilipp Wendel, Evelyn Ullrich, Nawid Albinger et al.|Cancers|2021Cited by 46
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectorsTobias Bexte, Evelyn Ullrich, Lacramioara Botezatu et al.|Molecular Therapy|2024Cited by 44
Immunotherapy with NK cells: recent developments in gene modification open up new avenuesLisa Marie Reindl, Evelyn Ullrich, Nawid Albinger et al.|OncoImmunology|2020Cited by 41
Nonviral technologies can pave the way for CAR-NK cell therapyTobias Bexte, Evelyn Ullrich, Lisa Marie Reindl|Journal of Leukocyte Biology|2023Cited by 19